Download presentation
1
SNHL Saisuree Nivatwongs ENT-PMK
2
Sensorineural hearing loss Introduction
History Physical examination Auditory testing Vestibular testing Laboratory testing Radiographic testing
3
Sensorineural hearing loss
Etiology Development & Hereditary disorder Infectious disorder Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic Immune disorder Bone disorder Neoplasms Endocrine & Metabolic disorder Disorder of unknown etiology **Sudden Sensorineural hearing loss**
4
History Unilateral / Bilateral Chronicity Underlying disease
Tinnitus / Vertigo Otalgia / Otorrhea Headache Eye symptoms Underlying disease Ototoxic drugs Hx of trauma Noise exposure Family Hx
5
Physical Examination Weber / Rinne test Otoscopy Cranial nerve
Stigmata of associated disease Generally no abnormality**
6
Auditory Testing Conventional audiometry Tympanometry
Acoustic reflex threshold Auditory brainstem response Electrocochleography Otoacoustic emission
7
Clinical evaluation Laboratory testing Vestibular testing
Fluorescent treponemal antibody absorption test : FTA-ABS Microhemagglutination test for Treponema pallidum : MHA-TP Venereal disease research laboratory : VDRL Routine hematologic studies Routine metabolic studies Vestibular testing Adjunct in selected patients Radiographic testing MRI with Gadolinium Retrocochlear hearing loss? Computed tomography Labyrinthine abnormality?
8
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
9
Development & Hereditary disorder
Waardenburg syndrome Large vestibular aqueduct syndrome Usher syndrome Alport syndrome
10
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
11
Suppurative labyrinthitis
Infectious disorder Labyrinthitis Serous labyrinthitis Abnormal process within the labyrinth Endolymphatic hydrops Hearing loss and vestibular dysfunction Permanent or transient Sudden onset of sensorineural hearing loss and acute vertigo Viral labyrinthitis is common Suppurative labyrinthitis Bacterial invasion of the inner ear Profound hearing loss and acute vertigo Caused by a fistula between the middle ear and the labyrinth Alternatively, the route of invasion can be meningogenic Most common etiology of deafness associated with meningitis
12
Infectious disorder Herpes zoster oticus Varicella-zoster infection
Most commonly associated with facial paralysis HL and vertigo can occur
13
Infectious disorder Measles Mumps
Not uncommon cause of deafness in children Bilateral HL Moderate-to-profound HL Vestibular function can be similarly affected Mumps Paramyxovirus infection Unilateral SNHL Unilateral deafness in otherwise healthy children Sudden deafness in adult Subclinical mumps infection in those without previous immunity
14
Infectious disorder Cytomegalovirus
Common cause of congenital and progressive HL in children Sudden SNHL in adults Hearing loss associated with AIDS may represent reactivation of latent CMV infections
15
Infectious disorder Syphilis Congenital or acquired syphilis
80% Symptomatic neurosyphilis HL in syphilis Meningolabyrinthitis Syphilitic HL Indistinguishable from Ménière’s disease Hennebert’s sign (a positive fistula test without middle ear disease) Tullio’s phenomenon (vertigo or nystagmus on exposure to high-intensity sound)
16
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
17
Pharmacologic disorder
Aminoglycosides Streptomycin, Kanamycin, Neomycin, Amikacin, Gentamicin, Tobramycin, and Netilmycin Death of the hair cell Different patterns of ototoxicity with different aminoglycosides Unilateral or asymmetric Reversibility of the HL Risk factors (1) presence of renal disease (2) longer duration of therapy (3) increased serum levels (4) advanced age (5) concomitant administration of other ototoxic drugs Ototopical preparations Neomycin, Gentamicin, and Tobramycin-containing Cochlear or vestibular ototoxicity Avoid the use of aminoglycoside-containing topical preparations in uninflamed ears with tympanic membrane perforations Ingredients of ototopical preparations also have ototoxic potential Polymyxin B, Propylene glycol, Acetic acid, Antifungal agents
18
Pharmacologic disorder
Antimalarials Quinine Tinnitus, SNHL, & Visual disturbances Chincinonism Tinnitus, headache, nausea, and disturbed vision Quinine appears to be primarily on hearing and usually is transient Permanent hearing loss may occur with large doses or in sensitive patients Loop diuretics Effect by blocking sodium and water reabsorption in the proximal loop of Henle Reversible SNHL Bilateral and symmetric Sudden in onset Alteration of endolymphatic ion concentration and endocochlear potential Risk factors (1) Renal failure (2) Rapid infusion (3) Aminoglycoside administration
19
Pharmacologic disorder
Salicylates Aspirin Tinnitus and reversible SNHL HL Dose-dependent Moderate-to-severe range SNHL, loss of otoacoustic emissions, reduced cochlear action potentials Alteration of the “tips” of auditory nerve fiber tuning curves Alteration in turgidity and motility of outer hair cells Nonsteroidal antiinflammatory drugs Naproxen, Ketoralac & Piroxicam Ototoxicity resulting from use of NSAIDs is rare Only reversible physiologic changes, without major morphologic changes
20
Pharmacologic disorder
Vancomycin Almost received Vancomycin & loop diuretics or aminoglycosides Ototoxicity Intravenously Permanent or transient SNHL Excreted by the kidney Renal failure Vancomycin half-life Increase ototoxicity Itself ototoxic Unclear Erythromycin Uncommon Partially Intravenously Reversible on discontinuation No reports - Newer macrolide - Clarithromycin - Azithromycin
21
Pharmacologic disorder
Cisplatinum Cell-cycle nonspecific cancer chemotherapeutic agent Dose-limiting SNHL Adults (25% to 86%) Children (84% to 100%) Bilateral / Irreversible Tinnitus or vertigo HL Dose-related Progressive outer hair cell loss Inner hair cells, neural structures and the stria vascularis are affected Nitrogen mustards Antineoplastic agents Mechlorethamine has Serious ototoxicity Limited use Severe toxic Shrinkage of the organ of Corti Loss of inner and outer hair cells
22
Pharmacologic disorder
Eflornithine Drug treatment of trypanosomiasis Some Pneumocystis carinii pneumonia, Cryptosporidiosis, Leishmaniasis, and Malaria Cause major and dose-related SNHL Vincristine and vinblastine The vinca alkaloids Potent neurotoxicity Peripheral neuropathy Cranial neuropathies, ataxia, and hearing loss Loss of hair cells and primary auditory neurons
23
Pharmacologic disorder
Lipid-lowering drugs Wallerian-like degeneration High doses of HMG-CoA reductase inhibitors Optic& vestibulocochlear nerve degeneration No clinically significant effect on vision or hearing Deferoxamine Iron-chelating agent Auditory and visual neurotoxicity Particularly with larger doses in younger patients The SNHL is reversible in some patients when the dosage is reduced
24
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
25
Trauma Head injury Blunt head injury alone
Concussive injury of the labyrinth Labyrinthine injury SNHL Temporal bone fracture Labyrinthine concussion Longitudinal fractures Similar to acoustic trauma Limited to the high F Worse at 4 kilohertz Transverse fractures Complete loss of auditory & vestibular function Penetrating injuries Subluxation ofthe stapes into the vestibule Profound SNHL
26
Trauma Noise-induced HL & Acoustic trauma
First published in the 1930s Common occupationally-induced disabilities Common in industry Caused by excessive noise exposure Temporary SNHL that recovers over the next 24 to 48 hours High intensity & repeated Permanent Outer hair cell Most effect More damage in - High-frequency sound - Continuous sound - Pure tones Symmetric & Bilateral HL Limited to 3 kHz, 4 kHz, and 6 kHz Greatest loss 4 kHz Progress rapidly in first 10 to 15 years of exposure
27
Noise-induced HL & Acoustic trauma
Common patterns Flat & downsloping losses Acoustic trauma Unilateral or asymmetric OSHA does not allow unprotected exposures greater than 90 dBA based on an 8 hour/day time weighted average (TWA) Variability Age, gender, race, and coexisting vascular disease No known way to predict susceptibility to NIHL Protection Earplugs or earmuffs Many hazardous noise exposures are not occupational in origin
28
Perilymphatic fistula
Trauma Barotrauma Unequalized pressure differentials between the middle and external ears Occurs during flying or underwater diving Pain, hyperemia and possible perforation of the tympanic membrane Edema and ecchymosis of the middle ear mucosa Conductive HL may result Perilymphatic fistula Pathologic communication between the perilymphatic space of the inner ear and the middle ear Congenital or acquired Occur at either the round or oval windows
29
Perilymphatic fistula
Congenital Occur in the stapes footplate with labyrinthine anomalies Such as Mondini dysplasia Communicate with the subarachnoid space and result in cerebrospinal fluid leak and possible meningitis Profound hearing loss Acquired Result of - Barotrauma - Direct trauma of temporal - Indirect trauma of temporal - Complication of stapedectomy Sudden SNHL and vertigo after a head injury, barotrauma, or heavy lifting or straining May be spontaneously Diagnosis Middle ear exploration
30
Trauma Irradiation Conventional fractionated irradiation of the temporal bone Fractionated irradiation Limited extent to treat vestibular schwannoma Difficult to determine because of the limited data available Stereotactic irradiation (“radiosurgery”) for vestibular schwannoma This modality Risk of SNHL High as with microsurgical removal
31
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
32
Neurologic disorders Multiple sclerosis
Multiple areas of CNS demyelination, inflammation, and glial scarring Age 20 to 30 years More common in women Cause Unknown 4% to 10% of MS SNHL Progressive or sudden Bilateral, unilateral, symmetric, or asymmetric Speech discrimination Normal or reduced Abnormalities of the ABR MRI Periventricular white-matter plaques on T2-weighted images
33
Benign intracranial hypertension
Neurologic disorders Benign intracranial hypertension Pseudotumor cerebri Increased intracranial pressure Without evidence of mass lesion, obstructive hydrocephalus, intracranial infection, or hypertensive encephalopathy Headache and visual blurring Pulsatile tinnitus SNHL and vertigo More in young, obese women SNHL Fluctuating, low-F Unilateral or bilateral Vertigo and aural fullness Diagnosis Papilledema CSF pressure > 200 mmH2O ABR abnormalities Management - Weight loss - Acetazolamide - Furosemide - Lumbar-peritoneal shunting
34
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
35
Vascular and hematologic disorders
Vertebrobasilar arterial occlusion Brainstem syndromes Anterior inferior cerebellar artery (AICA) Occlusion of AICA SNHL Thrombosis or embolism Area infarcted Inferior pons Acute AICA infarction Acute vertigo with N/V Facial paralysis, SNHL Tinnitus, gaze paralysis Loss of pain and temperature sensation on the face Ipsilateral Horner’s syndrome Migraine Headache and visual aura Basilar migraine Vertigo, SNHL Tinnitus, aural fullness Distortion & recruitment 46% Bilateral, low-F-SNHL Fluctuated HL Similarity, between basilar migraine and Ménière’s Dz. Drugs in basilar migraine No systematic study
36
Vascular and hematologic disorders
Waldenström’s macroglobulinemia Abnormally large amounts of IgM in the plasma Increased blood viscosity Subsequent ischemic lesions Progressive & sudden SNHL SNHL responded to alkylating agents or plasmapheresis
37
Vascular and hematologic disorders
Sickle cell anemia Incidence of SNHL ~ 22% of sickle cell disease Progressive or sudden Associated with sickle cell crises
38
Vascular and hematologic disorders
Leukemias & Lymphomas SNHL Leukemic infiltrates Inner ear hemorrhage Vascular occlusion Labyrinthine ischemia
39
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
40
Immune disorders Cogan’s syndrome
Attacks of acute non-syphilitic interstitial keratitis Auditory and vestibular dysfunction Unilateral or bilateral SNHL Severe vertigo, nausea, vomiting, and tinnitus Progresses to a profound loss over months Ophthalmologic findings If treated SNHL is responsive Aggressive treatment with steroids
41
Immune disorders Polyarteritis nodosa
Necrotizing vasculitis of small- and medium-sized arteries Myriad of findings, including weight loss, fatigue, fever, anorexia, arthritis, neuropathy, hypertension, renal failure, abdominal pain, and SNHL Biopsy Necrotizing vasculitis Unilateral or bilateral Facial paralysis also may be seen Management - Aggressive doses of steroids - Immunosuppressive drugs
42
Relapsing polychondritis
Immune disorders Relapsing polychondritis An inflammatory reaction in multiple cartilages The auricles 1st affected Arthritis and eye findings HL Conductive Sensorineural Mixed HL SNHL Sudden or progressive May be associated with vestibular disturbances Rx Steroids Immunosuppresive Dapsone
43
Wegener’s granulomatosis
Immune disorders Wegener’s granulomatosis Necrotizing granulomatous vasculitis involving principally the lungs, airway, and kidneys Usually Conductive HL CHL Involvement of the eustachian tube or middle ear SNHL If extends into the inner ear
44
Primary autoimmune inner ear disease
Immune disorders Primary autoimmune inner ear disease McCabe Bilateral SNHL responsive to immunosuppressive drugs Sudden or progressive HL Involves both ears Associated with vestibular symptoms Strongly mimic Ménière’s disease Humoral autoimmunity Abnormal Responsiveness of the HL to steroids or cytotoxic drugs The hallmark Used Methotrexate Reduce the need for continued high-dose steroids
45
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
46
Bone disorders Otosclerosis Primarily causes CHL Uncommonly
Progressive SNHL Especially in late disease CT images Radiolucent area surrounding the cochlea Advanced otosclerosis Bilateral profound mixed hearing loss
47
Bone disorders Paget’s disease Osteitis deformans Most common in older
~ 50% of Paget’s disease Conductive, SNHL or mixed Rarely fixed stapes footplate RX Calcitonin Eidronate disodium
48
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
49
Vestibular schwannoma
Neoplasms Vestibular schwannoma Most common neoplasm SNHL Originate from 8th CN Within the CPA or the IAC Approximately 80% of all CPA neoplasms Progressive unilateral SNHL Principally the high frequencies
50
Vestibular schwannoma
Neoplasms Vestibular schwannoma Speech discrimination is reduced out of proportion to the pure tone thresholds Sudden SNHL 10% of patient Unilateral or asymmetric tinnitus With or without hearing loss Mild or severe vestibular symptoms or may have none
51
Etiology Development & Hereditary disorder Infectious disorder
Pharmacologic disorder Trauma Neurologic disorder Vascular & Hematologic disorder Immune disorder Bone disorder Neoplasms Disorder of unknown etiology
52
Disorders of unknown etiology
Presbycusis Aging process Without other apparent etiology Age-related change Stiffness of the basilar membrane 30% of aged > 65 years Worse for high frequencies More severe in men Schuknecht 4 types
53
Presbycusis Neural presbycusis - Loss of auditory nerve fibers
Sensory presbycusis - Progressively hair cells loss - Steeply sloping HF-SNHL Strial presbycusis - Atrophy of the stria vascularis - Flat audiograms Neural presbycusis - Loss of auditory nerve fibers - Reduced speech discrimination out of proportion to their pure tone thresholds Cochlear presbycusis - Mechanical CHL
54
Disorders of unknown etiology
Ménière’s disease Fluctuant SNHL Tinnitus, episodic vertigo, and aural fullness Progresses, gradually or quickly HL Tinnitus “Buzzing” or “Roaring” Aural fullness Typically fluctuates Vertigo Several hours After attacks Fatigued for 24 hours or more Profound loss is rare Low F Commonly Bilateral in 30% to 50% Endolymphatic spaces dilatation of the inner ear
55
Disorders of unknown etiology
Ménière’s disease Vestibular destructive therapy No effective No therapy Effective in HL Medical therapy - Sodium-restricted diet - Diuretic administration Lack of an objective diagnostic test Idiopathic endolymphatic hydrops Other pathologic endolymphatic hydrops processes - Syphilis - Temporal bone trauma - Serous labyrinthitis - Stapedectomy - Autoimmune disease
56
Thank you for your attention
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.